U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
Reuters
Published Feb 16, 2018 22:25
U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
(Reuters) - The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's (L:AZN), (N:AZN) immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumours can't be surgically removed.
The approval was based on a trial testing on 713 patients whose cancer had not progressed after chemotherapy and radiation.
Imfinzi, chemically known as durvalumab, belongs to a new class of oncology drugs called PD-L1 inhibitors that block a mechanism tumours use to evade detection from the immune system.
Lung cancer is the leading cause of cancer death in the United States, with an estimated 222,500 new diagnoses and 155,870 deaths in 2017, according to the National Cancer Institute.
In 2017, the drug was approved to treat a type of bladder cancer in patients whose disease progressed despite chemotherapy.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.